Related Experiment Video

Updated: Jan 24, 2026

SUMO-Binding Entities SUBEs as Tools for the Enrichment, Isolation, Identification, and Characterization of the SUMO Proteome in Liver Cancer
08:29

SUMO-Binding Entities SUBEs as Tools for the Enrichment, Isolation, Identification, and Characterization of the SUMO Proteome in Liver Cancer

Published on: November 1, 2019

7.6K

Identification of TP53RK-Binding Protein (TPRKB) Dependency in TP53-Deficient Cancers

Moloy T Goswami1, Kelly R VanDenBerg1, Sumin Han1

  • 1Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan.

Molecular Cancer Research : MCR
|May 22, 2019
PubMed

Insights

Tumor protein 53 (TP53) mutations create vulnerabilities. Researchers found that TP53-deficient cancers depend on TP53RK-Binding Protein (TPRKB), offering a potential therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The tumor suppressor gene TP53 is frequently altered in human cancers.
  • Identifying vulnerabilities in TP53-altered cancers is crucial for developing targeted therapies.

Purpose of the Study:

  • To identify specific vulnerabilities in cancer cell lines with TP53 alterations.
  • To investigate the role of TP53RK-Binding Protein (TPRKB) in TP53-deficient cancers.

Main Methods:

  • Short hairpin RNA (shRNA) screening of cancer cell lines.
  • In vitro and in vivo proliferation assays.
  • TP53 reintroduction experiments.
  • Analysis of MDM2 amplification and EKC/KEOPS complex member depletion.

Main Results:

  • TPRKB knockdown significantly inhibited proliferation in TP53-mutated or TP53-null cancer cells, but not in TP53 wild-type cells.
  • Sensitivity to TPRKB knockdown was observed in cell lines with mutant TP53 or amplified MDM2.
  • TP53 indirectly mediates TPRKB degradation, suggesting a regulatory mechanism.

Conclusions:

  • TP53-deficient cancers exhibit a specific dependence on TPRKB.
  • TPRKB represents a potential therapeutic vulnerability in a wide range of TP53-altered cancers.

More Related Videos

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

12.7K
Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells12:55

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells

Published on: October 10, 2017

9.4K

Related Concept Videos

Conserved Binding Sites01:49

Conserved Binding Sites

Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
5.1K
Factors Affecting Protein-Drug Binding: Protein-Related Factors01:20

Factors Affecting Protein-Drug Binding: Protein-Related Factors

Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
535
The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
14.9K
Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
14.9K
Ligand Binding and Linkage00:49

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.5K
Protein-Drug Binding: Determination Methods01:22

Protein-Drug Binding: Determination Methods

Determining protein-drug binding can be achieved through indirect and direct methods, each providing valuable insights into the interaction between proteins and drugs.
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
634